These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29335912)

  • 1. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma.
    Beland B; Tsang RY; Sutherland G
    J Neurooncol; 2018 May; 137(3):667-669. PubMed ID: 29335912
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change.
    Goto H; Shimauchi T; Fukuchi K; Yokota N; Koizumi S; Aoshima M; Endo Y; Masuda Y; Miyazawa H; Kasuya A; Nakamura K; Ito T; Tokura Y
    Acta Derm Venereol; 2019 May; 99(6):612-613. PubMed ID: 30673109
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; RĂ©gis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
    Cagney DN; Alexander BM; Hodi FS; Buchbinder EI; Ott PA; Aizer AA
    J Neurooncol; 2016 Sep; 129(3):389-393. PubMed ID: 27401151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-irradiation with concurrent BRAF and MEK inhibitor therapy.
    Bergeron Gravel S; Bouffet E; Tabori U; Hawkins C; Tsang DS
    Pediatr Blood Cancer; 2021 May; 68(5):e28838. PubMed ID: 33258245
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID: 30396366
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.